info@mountequitygroup.com

Biogen surges ahead of key FDA decision amid mixed views on potential Alzheimer’s therapy

Mount Equity Group Tokyo Japan > News > Markets > Biogen surges ahead of key FDA decision amid mixed views on potential Alzheimer’s therapy